SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Core Insights - SELLAS Life Sciences Group has entered into an agreement with IMPACT-AML to conduct a clinical study evaluating SLS009, a selective CDK9 inhibitor, for acute myeloid leukemia (AML) [1][3] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications, with its lead product candidate, GPS, targeting the WT1 protein [4] - SLS009 is positioned as a potentially first and best-in-class small molecule CDK9 inhibitor, showing high response rates in AML patients with unfavorable prognostic factors [4] Collaboration Details - The IMPACT-AML initiative is a pan-European project aimed at advancing innovative treatments for AML, involving major research and clinical institutions across Europe [2] - The collaboration allows SELLAS to leverage IMPACT-AML's infrastructure for efficient patient enrollment and access to multiple European clinical sites [2][3] Clinical Study Plans - The clinical study will evaluate SLS009 in combination with azacitidine and venetoclax (AZA/VEN) in approximately 40 newly diagnosed AML patients with high-risk features [3][6] - Enrollment at U.S. sites is expected to begin in Q1 2026, followed by European sites in Q2 2026, pending regulatory and site readiness [3][6]